Nimodipine and Perfusion Changes After Stroke "NIMPAS"


Phase N/A Results

Trial Description

To evaluate the effect of oral nimodipine on reperfusion in acute ischemic cortical stroke.


  • Nimodipine (NimotopĀ®)Drug
    Other Names: The treatment group
    Intervention Desc: Calcium channel blocker (L-type calcium channels)

Trial Design

Prospective, double-blind, randomized trial of 50 patients.

Patient Involvement

Patients were randomized to receive either nimodipine 120 mg/d orally in 4 divided doses (30 mg every 6 hours) or an equivalent regimen of placebo for 14 days.


Type Measure Time Frame Safety Issue
Primary CBF was assessed with the use of HMPAO SPECT prior to initiation of therapy, 24 hours after pretherapy scan and at 3 months. Neurological impairment was assessed concurrently with SPECT studies by a modified Canadian Neurological Scale (CNS). Functional disability and tissue loss were measured at 3 months by the Barthel Index (BI) and CT, respectively.